Osteoporosis treatment discontinued

Protelos (strontium ranelate) has been withdrawn worldwide for commercial reasons.

Further information

Manufacturer: Servier

The drug was licensed to treat severe osteoporosis in postmenopausal women and adult men at high risk of fracture for whom other osteoporosis treatments were unsuitable (eg, because of contraindications or intolerance).

The manufacturer of Protelos, Servier, decided to withdraw the drug after its indications were restricted over cardiovascular concerns and the number of patients treated with the drug declined.

Servier has been liaising with the relevant patient and professional organisations, such as the National Osteoporosis Society, the British Society of Rheumatology and the Primary Care Rheumatology Society, to make them aware of the discontinuation.

GPs are advised to identify and review any patients who are currently prescribed strontium ranelate and discuss alternative treatment options with them. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases